CompletedNCT02501265
Adaptive Medication Strategies to Support Smoking Cessation
About this title
Read the official source —Medication studyAges 18+United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- DurhamSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: June 6, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 188
- Sponsor
- Duke University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Psychotherapy / behavioral intervention, Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT02501265
- Official title
Show the full official title
Randomized Controlled Smoking Cessation Trial on Adaptive Pharmacotherapy
Get this study by email
Recruitment & locations
CompletedDurham
Questions about this study
Who is behind this study?
The study sponsor is Duke University, a university.
Did this study involve medication?
Yes. The study involved medication, including Varenicline Adaptive Protocol and Nicotine Adaptive Protocol.
Who was this study for?
Listed age limits: from 18 years.
